We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers

By LabMedica International staff writers
Posted on 29 Sep 2022
Image: Researchers have suggested effective preparation for the next pandemic (Photo courtesy of Cultura RM Exclusive/Matt Lincoln)
Image: Researchers have suggested effective preparation for the next pandemic (Photo courtesy of Cultura RM Exclusive/Matt Lincoln)

The lack of early COVID-19 PCR testing capacity had a knock-on effect on other health services in 2020. This included delaying the ability to make sure hospitals were COVID-secure and patients had surgery as safely as possible, and slowing down the identification of people with COVID-19 in the community – which delayed contact tracing. The risk of another pandemic like COVID-19 happening is ever-present: there have been outbreaks of infectious disease throughout history. But nobody can say for sure when it will happen. Now, researchers have suggested that a system of reservist lab scientists should to be set up now to provide surge capacity that will help respond faster – and more effectively – to future outbreaks of infectious disease. They considered a number of options for providing scientific surge capacity and concluded that the best scenario would be a mix of highly skilled paid reservists, and volunteers who could be called on when required and trained rapidly.

In their report, published in the journal The BMJ, researchers at University of Cambridge (Cambridge, UK) suggest that effective preparation for the next pandemic includes recruiting a relatively small number of highly skilled scientists, who would be paid on retainer, to help in the initial phases of an emergency. It would also involve a large reserve of volunteer staff to provide essential testing capacity; these people would not need to have specialist skills but could be trained quickly in an emergency and paid only when needed. Those working in sectors of the economy likely to close during a pandemic - such as entertainment and hospitality - would be ideal candidates as voluntary reserves, the researchers say.

In their paper the scientists compare COVID-19 with other large-scale emergencies including war, where the military has a system of reservists for built-in surge capacity. But they say that unlike the military where reservists serve to deter warfare, having an ‘always-on’ capacity to deal with public health emergencies wouldn’t do anything to deter a new pandemic from emerging – and that’s why there has always been a pressure to close labs and streamline public health services. Their suggested solution does not require sustained, cross-party political will to fund so is more likely to succeed; the researchers acknowledge there are many other pressures on the UK economy that must take priority. They recommend that other countries should consider their requirements for surge capacity based on their own circumstances.

“There’s an extent to which the emergence of an infectious disease is a random process, but a pandemic like COVID-19 is guaranteed to happen again at some point,” said Dr Jordan Skittrall in the University of Cambridge’s Department of Pathology and first author of the report. “In the UK we’re in the privileged position of having the right scientific skills to respond to the next big outbreak. But we need to make sure that we have these people ready, so that when something does happen they can hit the ground running.”

Related Links:
University of Cambridge 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Drug Testing Assays
Atellica DT 250 Analyzer

Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more